![](https://investorshub.advfn.com/uicon/335210.png?cb=1711016435)
Monday, February 08, 2021 8:32:36 PM
D1sclaimer: I am not a financial advisor or a stock promoter. I am an investor, Period! Do your own DD and make your own investment decisions.
Recent VBIV News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/02/2024 08:05:34 PM
- VBI Vaccines Provides an Update on its Restructuring Proceedings • Business Wire • 08/02/2024 08:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/30/2024 02:28:18 PM
- VBI Vaccines Initiates Restructuring Proceedings Under CCAA to Implement a Review of its Strategic Alternatives • Business Wire • 07/30/2024 01:55:00 PM
- VBI Vaccines Announces Results of Annual General Meeting • Business Wire • 06/25/2024 08:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 12:00:20 PM
- VBI Vaccines Announces New Tumor Response Data from Ongoing Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma Patients • Business Wire • 05/29/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/24/2024 09:00:33 PM
- VBI Vaccines Announces Poster Presentation at 2024 ASCO Annual Meeting Highlighting New Interim Phase 2b Data from VBI-1901 in Recurrent Glioblastoma Patients • Business Wire • 05/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2024 08:18:29 PM
- VBI Vaccines Reports First Quarter 2024 Financial Results • Business Wire • 05/15/2024 08:00:00 PM
- VBI Vaccines Reports Full Year 2023 Financial Results • Business Wire • 04/16/2024 12:00:00 PM
- VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • Business Wire • 04/11/2024 08:05:00 PM
- VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules • Business Wire • 04/09/2024 06:45:00 PM
- VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma • Business Wire • 04/03/2024 12:00:00 PM
- VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform • Business Wire • 04/02/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 01:34:40 PM
- VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences • Business Wire • 02/14/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/06/2024 09:23:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/23/2024 09:15:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/11/2024 09:15:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/26/2023 09:15:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/12/2023 09:15:16 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/29/2023 09:15:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 01:00:27 PM
Maybacks Global Entertainment and ZEASN Technology Private Ltd. Sign Global Licensing Agreement • AHRO • Aug 8, 2024 7:00 AM
SANUWAVE Will Host a Conference Call on August 13, 2024 at 8:30 AM (ET) to Present Q2 Financial Results • SNWV • Aug 8, 2024 6:59 AM
Kona Gold Beverage Inc. Signs Letter of Intent with Bemax, Inc. to Sell Kona Gold, LLC • BMXC • Aug 7, 2024 10:00 AM
Btab Ecommerce Group, Inc. Launches Investor Connect AI Chatbot for Enhanced Investor Engagement and Lead Generation • BBTT • Aug 7, 2024 9:00 AM
Hydromer, Inc. Announces Preliminary Unaudited Second Quarter 2024 Financial Results and Provides Business Update • HYDI • Aug 7, 2024 8:52 AM
North Bay Resources Announces Mt. Vernon Gold Mine Startup, Sierra County, California • NBRI • Aug 5, 2024 9:00 AM